Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity
Ji-Yeon Shin,
Zhi-Hui Fang,
Zhao-Xue Yu,
Chuan-En Wang,
Shi-Hua Li, , and
Xiao-Jiang Li
Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322
Correspondence to Xiao-Jiang Li: xiaoli{at}genetics.emory.edu
Abstract:
Huntington disease (HD) is characterized by the preferentialloss of striatal medium-sized spiny neurons (MSNs) in the brain.Because MSNs receive abundant glutamatergic input, their vulnerabilityto excitotoxicity may be largely influenced by the capacityof glial cells to remove extracellular glutamate. However, littleis known about the role of glia in HD neuropathology. Here,we report that mutant huntingtin accumulates in glial nucleiin HD brains and decreases the expression of glutamate transporters.As a result, mutant huntingtin (htt) reduces glutamate uptakein cultured astrocytes and HD mouse brains. In a neurongliacoculture system, wild-type glial cells protected neurons againstmutant htt-mediated neurotoxicity, whereas glial cells expressingmutant htt increased neuronal vulnerability. Mutant htt in culturedastrocytes decreased their protection of neurons against glutamateexcitotoxicity. These findings suggest that decreased glutamateuptake caused by glial mutant htt may critically contributeto neuronal excitotoxicity in HD.
Abbreviations used in this paper: AD, Alzheimer's disease; DHK,dihydrokainate; DIV, days in vitro; GFAP, glial fibrillary acidicprotein; GLT-1, glutamate transporter-1; GLAST, glutamate/aspartatetransporter; HD, Huntington's disease; htt, huntingtin; MAP2,microtubule-associated protein 2; MSNs, medium-sized spiny neurons;MTT, 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazoliumbromide; PolyQ, polyglutamine.
The editors suggest the following Related Resources on Science sites:
A critical role of astrocyte-mediated nuclear factor-{kappa}B-dependent inflammation in Huntington's disease.
H.-Y. Hsiao, Y.-C. Chen, H.-M. Chen, P.-H. Tu, and Y. Chern (2013)
Hum. Mol. Genet.
22, 1826-1842
|Abstract »|Full Text »|PDF »
Distinct roles for Toll and autophagy pathways in double-stranded RNA toxicity in a Drosophila model of expanded repeat neurodegenerative diseases.
S. E. Samaraweera, L. V. O'Keefe, G. R. Price, D. J. Venter, and R. I. Richards (2013)
Hum. Mol. Genet.
|Abstract »|Full Text »|PDF »
Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability.
G. Cisbani, T. B. Freeman, D. Soulet, M. Saint-Pierre, D. Gagnon, M. Parent, R. A. Hauser, R. A. Barker, and F. Cicchetti (2013)
Brain
136, 433-443
|Abstract »|Full Text »|PDF »
Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease.
B. Tang, K. Becanovic, P. A. Desplats, B. Spencer, A. M. Hill, C. Connolly, E. Masliah, B. R. Leavitt, and E. A. Thomas (2012)
Hum. Mol. Genet.
21, 3097-3111
|Abstract »|Full Text »|PDF »
R6/2 Huntington's Disease Mice Develop Early and Progressive Abnormal Brain Metabolism and Seizures.
E. Cepeda-Prado, S. Popp, U. Khan, D. Stefanov, J. Rodriguez, L. B. Menalled, D. Dow-Edwards, S. A. Small, and H. Moreno (2012)
J. Neurosci.
32, 6456-6467
|Abstract »|Full Text »|PDF »
Truncated N-terminal huntingtin fragment with expanded-polyglutamine (htt552-100Q) suppresses brain-derived neurotrophic factor transcription in astrocytes.
L. Wang, F. Lin, J. Wang, J. Wu, R. Han, L. Zhu, G. Zhang, M. DiFiglia, and Z. Qin (2012)
Acta Biochim Biophys Sin
44, 249-258
|Abstract »|Full Text »|PDF »
Nuclear Factor-{kappa}B Contributes to Neuron-Dependent Induction of Glutamate Transporter-1 Expression in Astrocytes.
M. Ghosh, Y. Yang, J. D. Rothstein, and M. B. Robinson (2011)
J. Neurosci.
31, 9159-9169
|Abstract »|Full Text »|PDF »
Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications.
Increased energy metabolism rescues glia-induced pathology in a Drosophila model of Huntington's disease.
M.-T. Besson, P. Dupont, Y.-W. C. Fridell, and J.-C. Lievens (2010)
Hum. Mol. Genet.
19, 3372-3382
|Abstract »|Full Text »|PDF »
Altered Manganese Homeostasis and Manganese Toxicity in a Huntington's Disease Striatal Cell Model Are Not Explained by Defects in the Iron Transport System.
B. B. Williams, G. F. Kwakye, M. Wegrzynowicz, D. Li, M. Aschner, K. M. Erikson, and A. B. Bowman (2010)
Toxicol. Sci.
117, 169-179
|Abstract »|Full Text »|PDF »
In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects.
M. Faideau, J. Kim, K. Cormier, R. Gilmore, M. Welch, G. Auregan, N. Dufour, M. Guillermier, E. Brouillet, P. Hantraye, et al. (2010)
Hum. Mol. Genet.
19, 3053-3067
|Abstract »|Full Text »|PDF »
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.
Mutant Huntingtin in Glial Cells Exacerbates Neurological Symptoms of Huntington Disease Mice.
J. Bradford, J.-Y. Shin, M. Roberts, C.-E. Wang, G. Sheng, S. Li, and X.-J. Li (2010)
J. Biol. Chem.
285, 10653-10661
|Abstract »|Full Text »|PDF »
Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms.
J. Bradford, J.-Y. Shin, M. Roberts, C.-E. Wang, X.-J. Li, and S. Li (2009)
PNAS
106, 22480-22485
|Abstract »|Full Text »|PDF »
Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond.
H. Ilieva, M. Polymenidou, and D. W. Cleveland (2009)
J. Cell Biol.
187, 761-772
|Abstract »|Full Text »|PDF »
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
J. Palazuelos, T. Aguado, M. R. Pazos, B. Julien, C. Carrasco, E. Resel, O. Sagredo, C. Benito, J. Romero, I. Azcoitia, et al. (2009)
Brain
132, 3152-3164
|Abstract »|Full Text »|PDF »
The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway.
M. Cui, R. Aras, W. V. Christian, P. M. Rappold, M. Hatwar, J. Panza, V. Jackson-Lewis, J. A. Javitch, N. Ballatori, S. Przedborski, et al. (2009)
PNAS
106, 8043-8048
|Abstract »|Full Text »|PDF »
High efficiency adenovirus-mediated expression of truncated N-terminal huntingtin fragment (htt552) in primary rat astrocytes.
L. Wang, F. Lin, J. Wu, and Z. Qin (2009)
Acta Biochim Biophys Sin
41, 325-334
|Abstract »|Full Text »|PDF »
Dysfunctional Cell-Cell Signaling in the Neurovascular Unit as a Paradigm for Central Nervous System Disease.
Differential Activities of the Ubiquitin-Proteasome System in Neurons versus Glia May Account for the Preferential Accumulation of Misfolded Proteins in Neurons.
S. Tydlacka, C.-E. Wang, X. Wang, S. Li, and X.-J. Li (2008)
J. Neurosci.
28, 13285-13295
|Abstract »|Full Text »|PDF »
Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin.
C.-E. Wang, H. Zhou, J. R. McGuire, V. Cerullo, B. Lee, S.-H. Li, and X.-J. Li (2008)
J. Cell Biol.
181, 803-816
|Abstract »|Full Text »|PDF »
Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease.
C.-E. Wang, S. Tydlacka, A. L. Orr, S.-H. Yang, R. K. Graham, M. R. Hayden, S. Li, A. W.S. Chan, and X.-J. Li (2008)
Hum. Mol. Genet.
17, 2738-2751
|Abstract »|Full Text »|PDF »
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.
M. Bjorkqvist, E. J. Wild, J. Thiele, A. Silvestroni, R. Andre, N. Lahiri, E. Raibon, R. V. Lee, C. L. Benn, D. Soulet, et al. (2008)
J. Exp. Med.
205, 1869-1877
|Abstract »|Full Text »|PDF »
Expanded-Polyglutamine Huntingtin Protein Suppresses the Secretion and Production of a Chemokine (CCL5/RANTES) by Astrocytes.
S.-Y. Chou, J.-Y. Weng, H.-L. Lai, F. Liao, S. H. Sun, P.-H. Tu, D. W. Dickson, and Y. Chern (2008)
J. Neurosci.
28, 3277-3290
|Abstract »|Full Text »|PDF »
Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice.
J. Wang, C.-E. Wang, A. Orr, S. Tydlacka, S.-H. Li, and X.-J. Li (2008)
J. Cell Biol.
180, 1177-1189
|Abstract »|Full Text »|PDF »
Histone Deacetylase Inhibition Modulates Kynurenine Pathway Activation in Yeast, Microglia, and Mice Expressing a Mutant Huntingtin Fragment.
F. Giorgini, T. Moller, W. Kwan, D. Zwilling, J. L. Wacker, S. Hong, L.-C. L. Tsai, C. S. Cheah, R. Schwarcz, P. Guidetti, et al. (2008)
J. Biol. Chem.
283, 7390-7400
|Abstract »|Full Text »|PDF »
AKT-sensitive or insensitive pathways of toxicity in glial cells and neurons in Drosophila models of Huntington's disease.
J.-C. Lievens, M. Iche, M. Laval, C. Faivre-Sarrailh, and S. Birman (2008)
Hum. Mol. Genet.
17, 882-894
|Abstract »|Full Text »|PDF »
N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking.
A. L. Orr, S. Li, C.-E. Wang, H. Li, J. Wang, J. Rong, X. Xu, P. G. Mastroberardino, J. T. Greenamyre, and X.-J. Li (2008)
J. Neurosci.
28, 2783-2792
|Abstract »|Full Text »|PDF »
Expansions of CAG{middle dot}CTG repeats in immortalized human astrocytes.
Selective defect of in vivo glycolysis in early Huntington's disease striatum.
W. J. Powers, T. O. Videen, J. Markham, L. McGee-Minnich, J. V. Antenor-Dorsey, T. Hershey, and J. S. Perlmutter (2007)
PNAS
104, 2945-2949
|Abstract »|Full Text »|PDF »
The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.
E. Rockabrand, N. Slepko, A. Pantalone, V. N. Nukala, A. Kazantsev, J. L. Marsh, P. G. Sullivan, J. S. Steffan, S. L. Sensi, and L. M. Thompson (2007)
Hum. Mol. Genet.
16, 61-77
|Abstract »|Full Text »|PDF »